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Abstract The relationship of migraine with cardiovas-
cular diseases has been clariﬁed by many studies, and
currently, migraine is suggested to be a systematic vascu-
lopathy. Inﬂammation, thrombosis and impaired vascular
reactivity are the underlying pathophysiological mecha-
nisms of the vasculopathy. In the present study, we aimed
to investigate the relationship between prolactin levels and
subclinical atherosclerosis risk factors such as soluble
CD40 ligand (sCD40L) and high-sensitivity CRP (hsCRP)
in migraine patients during interictal period. Fifty female
migraine patients and age-matched 25 female control cases
were enrolled in the study. Migraine diagnosis was settled
according to the ICHD-II diagnostic criteria. A question-
naire was completed about the existence of vascular risk
factors. Serum samples were used to measure sCD40L,
hsCRP and prolactin levels. No difference was found
between the prolactin levels of the migraine patients and
the controls. The sCD40L levels were signiﬁcantly higher
in migraine patients (p\0.001). High-sensitivity CRP
levels showed no difference between the groups. There was
no correlation between prolactin, sCD40L, and hs-CRP
levels in migraine patients. We consider that the migraine
patients are prone to subclinical atherosclerosis, but this
tendency is independent of prolactin levels.
Keywords Migraine  Prolactin  sCD40L 
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Introduction
Migraine is a kind of headache which is caused by the
alterations in trigeminovascular system, but the patho-
physiological mechanisms have not still been fully delin-
eated. Today, it is known that the vascular alterations
are not limited to cranial vessels, and migraine is suggested
to be a systemic vasculopathy [1]. The vasculopathy of
migraine is thought to reﬂect the endothelial dysfunction
and impaired vascular reactivity. The activation of the
platelets and the coagulation factors [2], the increased
secretion of von Willebrand factor and tissue plasminogen
activator from endothelium [3], the decrease in the circu-
lating endothelial progenitor cells [4], which are all seen in
migraine, support this theory. The demonstration of similar
C-reactive protein (CRP) levels in migraineurs and healthy
control subjects in recent studies [5, 6], although it had
been found high in previous studies [7–9], necessitates new
investigations and data about this issue.
The increasing number of studies in the past decade
showed that the risk of cardiovascular disease is increased
in migraine [10–13]. Cytokines and cytokine-inducible
inﬂammatory molecules are predictors of cardiovascular
events. Elevated high-sensitivity CRP (hsCRP), interleukin
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DOI 10.1007/s10194-011-0306-86 and soluble CD40 ligand (sCD40L) levels are associated
with the increased risk of cardiovascular disease [14, 15].
Soluble CD40L is a ligand of glycoprotein IIb-IIIa receptor
and is involved in thrombus stabilization and platelet
activation. It is a reliable predictor of cardiovascular dis-
ease [16].
Prolactin, secreted from anterior pituitary gland and
meanwhile also synthesized by various immune system
cells, has been reported to cause a tendency to the car-
diovascular diseases. On the other hand, hyperprolactine-
mia induces migraine attacks [17] and also plays a role in
other primary headache syndromes [18]. It is known that
dopaminergic dysfunction is responsible from autonomic
symptoms such as nausea and yawning [19].
In this study, we aimed to investigate the sCD40L,
prolactin and hsCRP levels in migraine patients during
interictal period and their relationship with migraine sub-
types and attack frequency.
Materials and methods
Fifty female migraine patients and age-matched 25 female
control subjects were enrolled in the study. Migraine
diagnosis was settled according to the International Clas-
siﬁcation of Headache Disorders-II diagnostic criteria [20].
Twenty-three patients had migraine with aura, while the
rest had migraine without aura. The control subjects were
enrolled as healthy individuals who had no headache of any
kind. The study was approved by the local Ethics Com-
mittee, and all patients gave their informed consent to
participate in the study. Exclusion criteria included preg-
nancy, disorders and drugs which affect the prolactin levels
such as butyrophenones, phenothyozines, reserpine or
methyldopa, history of prolactinoma, hypothyroidism,
chronic renal failure and cirrhosis. A questionnaire was
completed about the existence of vascular risk factors such
as hypertension, diabetes, smoking and family history of
cardiovascular diseases. Migraine headache attack fre-
quency was noted as the number of attacks per month.
Body mass index (BMI) was calculated on the basis of
World Health Organization (WHO) recommendations.
Serum samples were collected from an antecubital vein
without using a tourniquet, between 08:30 and 09:00 a.m.
after overnight fasting. For hsCRP, sCD40L and prolactin,
venous blood samples were centrifuged within 15 min at
3,000 rpm for 10 min, and the supernatant serum samples
weretransferredintopolypropylenetubesat-80Cuntilthe
assays were performed. Soluble CD40L and hsCRP levels
were measured by ELISA (Biosource, Immunoassay-kit,
USA; DRG Inc., USA, respectively) and prolactin levels by
chemiluminesense immunoassay (DPC, Immulite 2000,
USA). The participants’ serum fasting glucose levels were
measured using the glucose oxidase technique (Konelab 60,
Finland). Cholesterol esterase enzymatic assays (Konelab
60,Finland)wereusedtomeasuretotalcholesterolandhigh-
density lipoprotein-cholesterol (HDL-C). Triglyceride lev-
els were measured by the lipase technique (Konelab 60,
Finland). Low-density lipoprotein-cholesterol (LDL-C)
levels were calculated according to Friedewald’s formula.
Values of the platelet count and mean platelet volume were
obtained from whole blood count analysis.
Statistical analysis
All statistical analyses were performed by using SPSS 11.5
software for Windows. Data were expressed as
mean ± SD. The normality of the distribution of all vari-
ables was assessed by the Kolmogorov–Smirnov test.
Student’s t test and Pearson correlation analyses were used
for normally distributed variables. The Mann–Whitney
U test and Spearman rank correlation test were used for
non-parametric variables. Logistic regression model was
performed for adjusting for BMI. P values \0.05 were
considered statistically signiﬁcant.
Results
The characteristics of the migraine patients and the control
subjects are shown in Table 1. Age, anthropometric values,
blood pressure, serum fasting glucose and lipid levels did
not differ between the two groups. BMI was higher in the
migraine group (p\0.05). No difference was found
between the prolactin levels of the migraine patients and
the controls. The sCD40L levels were signiﬁcantly higher
in migraine patients (p\0.001). High-sensitivity CRP
levels showed no difference between the groups. There was
no correlation between the prolactin, sCD40L and hs-CRP
levels in migraine patients (p[0.05, for all). Soluble
CD40L remained signiﬁcantly high in the migraine group
after adjusting for BMI of both the groups (p = 0.002).
Mean platelet volume of migraine patients was signiﬁ-
cantly higher than that of the control group (p\0.05) and
was correlated with sCD40L levels (r = 0.362, p\0.05).
No difference was found between migraine with aura
and migraine without aura groups regarding the sCD40L,
hsCRP and prolactin levels (Table 2). When the migraine
patients were subdivided according the attack frequency,
sCD40L, hsCRP and prolactin levels were indifferent
among the frequent (4 or more attacks/month) and seldom
(less than 4 attacks/month) attack groups (Table 3). Family
history of migraine and cardiovascular disease were not
associated with these parameters (p[0.05, for all).
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The main ﬁnding in our study was the elevated sCD40L
levels in migraine patients. We consider that this is a new
data related to the association of migraine and vascular
diseases. There are several studies reporting the association
of sCD40L with cardiovascular diseases. Soluble CD40L
was suggested to be a predictor for myocardial infarction
and stroke [21–23]. In the studies, where the acute coro-
nary patients were enrolled, sCD40L was found as a mar-
ker of inﬂammatory thrombotic activity and found related
with further increased cardiovascular events [21, 22].
Recently, CD40/CD40L pathway activation and a sub-
sequent proinﬂamatory milieu were reported in diseases
such as obesity [24, 25], diabetes mellitus [26] and
hypertension [27]. Whether migraine patients constitute a
low- or high-risk group for cardiovascular disease is
obscure, but high-sCD40L levels in migraine patients in
our study support the presence of a vascular damage in
migraine.
CD40L belongs to the tumor necrosis family and is a
transmembrane protein expressed by heamatopoetic cell
typessuchasTlymphocytes,monocytesandplateletsaswell
as by nonheamatopoetic cells like endothelial and smooth
Table 1 The clinical and
laboratory characteristics of all
participants
Ns non-signiﬁcant, BP blood
pressure, MPV mean platelet
volume, hsCRP high-sensitivity
C-reactive protein, sCD40L
soluble CD40 ligand
Migraine subjects (n = 50) Control subjects (n = 25) p
Age (years) 38.0 ± 8.6 34.4 ± 7.8 Ns
Hypertension (%) 9.3 9.0 Ns
Diabetes mellitus (%) 4.4 0 Ns
Smoking (%) 42.4 50 Ns
BMI (kg/m
2) 26.54 ± 5.52 23.98 ± 3.18 \0.05
Systolic BP (mmHg) 118.09 ± 17.4 123.63 ± 23.77 Ns
Diastolic BP (mmHg) 77.44 ± 16.34 77.27 ± 11.03 Ns
Glucose (mg/dl) 91.76 ± 10.76 93.85 ± 22.8 Ns
Cholesterol (mg/dl) 189.88 ± 38.04 183.42 ± 40.28 Ns
Triglyceride (mg/dl) 106.21 ± 44.54 102.85 ± 53.97 Ns
LDL (mg/dl) 119.92 ± 32.38 111.68 ± 32.90 Ns
HDL (mg/dl) 50.03 ± 12.52 49.29 ± 15.88 Ns
Platelet (/mm
3) 274361 ± 59207 263062 ± 60698 Ns
MPV (fL) 9.53 ± 1.4 8.7 ± 0.92 \0.05
Prolactin (ng/mL) 11.34 ± 8.63 10.89 ± 5.0 Ns
hs-CRP (mg/L) 4.28 ± 4.01 3.91 ± 3.89 Ns
sCD40L (ng/mL) 11.92 ± 5.26 7.72 ± 3.6 \0.001
Table 2 Soluble CD40L, hsCRP and prolactin levels in migraineurs with aura and without aura subgroups
Migraineurs with aura (n = 23) Migraineurs without aura (n = 27) p
sCD40L (ng/mL) 11.73 ± 4.52 12.08 ± 5.9 Ns
hsCRP (ng/L) 4.06 ± 3.98 4.46 ± 4.1 Ns
Prolactin (ng/mL) 9.45 ± 4.77 12.95 ± 10.74 Ns
Ns non-signiﬁcant, hsCRP high-sensitivity C-reactive protein, sCD40L soluble CD40 ligand
Table 3 Soluble CD40L, hsCRP and prolactin levels in migraineurs with frequent (4 or more attacks/month) and seldom (less than 4 attacks/
month) headache attacks
Frequent migraine attacks (n = 33) Seldom migraine attacks (n = 17) p
sCD40L (ng/mL) 11.87 ± 4.55 14.09 ± 6.8 Ns
hsCRP (ng/L) 4.40 ± 3.72 4.76 ± 5.04 Ns
Prolactin (ng/mL) 9.70 ± 5.75 10.60 ± 3.74 Ns
Ns non-signiﬁcant, hsCRP high-sensitivity C-reactive protein, sCD40L soluble CD40 ligand
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123muscle cells. Soluble form is particularly produced by
platelet activation [28], is associated with plaque instability
and is a predictor of the plaque complications [29, 30].
Moreover, CD40L is able to promote overexpression of tis-
sue factor, a glycoprotein that has a crucial role in the acti-
vation of coagulation cascade [31]. In order to clarify if the
increase of sCD40L in migraine patients is concordant with
platelet activation, we compared between the mean platelet
volume of two groups. It is a reliable marker of platelet
activation such as platelet aggregation, secretion of throm-
boxane A2, platelet factor 4 and thromboglobulin [32, 33].
Wefoundthatthemeanplateletvolume ofmigrainepatients
was signiﬁcantly higher than that in the controls, and it was
correlated with CD40L levels in migraine. This impresses
that the high sCD40L levels in our study were mainly
dependent on platelet activation.
Soluble CD40L additionally has inﬂammatory property
including expression of adhesive molecule, chemokines
and metalloproteinases [29], which is different from the
inﬂammatory pathway of CRP [21, 27]. Matrixmetallo-
proteinase 9, whose levels are found high during migraine
attacks, degrades laminin, collagen type IV, a critical
component of brain blood levels [34]. Soluble CD40L also
induces the secretion of other proinﬂammatory cytokines
such as interleukin 1 (IL-1), IL-6, IL-8, IL-10 and tumor
necrosis factor (TNF) from monocytes [35], dentritic cells
[36], ﬁbroblasts [37] and epithelial cells [38]. TNF alpha,
IL-6, IL1 beta and IL10 were found to be increased during
migraine attacks [39]. In the present study, since we did not
measure the levels of these proinﬂammatory cytokines, it is
not possible to conclude any association of the proinﬂam-
matory property of sCD40L with the inﬂammation in
migraine.
Another ﬁnding of our study is that the hsCRP levels of
the migraineurs and the control cases were not signiﬁcantly
different. There are several studies reporting modest
hsCRP increase in migraine patients, but this elevation was
only noted in the migraine without aura group which was
actually not associated with cardiovascular diseases [7–9].
A recent study carried on large number of case groups
demonstrated no difference in hsCRP levels in migraine
patients and non-migraineurs [5]. The elevation of hsCRP
levels is a marker of inﬂammatory process, especially in
the cardiovascular diseases, infection and malignacies.
However, as known, low CRP levels can also be seen in
diseases with marked tissue inﬂammation such as systemic
lupus erythematosus [40]. Normal hsCRP value in
migraine should not mean that there is no inﬂammation or
no risk of cardiovascular disease in migraine. Other path-
ways, such as the inﬂammatory CD40 property, may be
involved in the inﬂammatory process of migraine.
In our study, we found similar prolactin levels between
the migraine and control groups during interictal period.
Our results are concordant with two other studies reporting
normal prolactin levels in migraine [41, 42]. It was
hypothesized that the increased dopaminergic activity is
responsible from prodromal, clinical and postdromal
symptoms [19, 43] and, therefore, a decrease in prolactin
levels should be expected during migraine attacks. Con-
veniently, Masoud and Fakharian [44] found a signiﬁcant
decrease in prolactin levels during the headache attack in
migraineurs. Another study reported high prolactin levels
during migraine attack, but the study was carried on sub-
jects who had microprolactinomas [17]. Since we measured
the prolactin levels only during the interictal period, we
could not compare our results with these two studies.
Although prolactin has been reported to create a ten-
dency to the cardiovascular diseases [45–48], our study
demonstrated no correlation of prolactin with sCD40L and
hs-CRP. It is known that increased prolactin levels in cases
with prolactinoma cause obesity, insulin resistance, an
increase in homocysteine levels and low-grade inﬂamma-
tion and subsequently a tendency to cardiovascular diseases
[46, 47]. High prolactin levels stimulating sympathetic
tonus cause preeclempsia in pregnancy [49]. Recently, a
relationship was found between prolactin levels, blood
pressure and arterial stiffness, and prolactin was accused of
accelerated atherosclerosis in women with early menopause
[45]. The demonstration of the intense prolactin receptor
expression on advanced human coronary atherosclerotic
plaques supports the role of prolactin on the development of
atherosclerosis [48].
The present study demonstrated that the sCD40L levels
are elevated in female migraine patients during interictal
period. The small number of the groups and the omission of
other hormones, such as estrogens and progesterone, which
inﬂuence the biologic action of prolactin were the limita-
tions of the study. We consider that our ﬁndings should be
supported by investigations during the attack period and
also in male migraineurs. Further prospective studies are
needed to clarify the mechanisms underlying the associa-
tion between migraine and cardiovascular diseases.
Conﬂict of interest None.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution and reproduction in any medium, provided the original
author(s) and source are credited.
References
1. Tietjen GE (2009) Migraine as a systematic vasculopathy.
Cephalalgia 29:989–996
2. D’Andrea G, Toldo M, Cortelazzo S, Milone FF (1982) Platelet
activity in migraine. Headache 22:207–212
358 J Headache Pain (2011) 12:355–360
1233. Tietjen GE, Al Qasmi MM, Athanas K, Dafer RM, Khuder SA
(2001) Increased von Willebrand factor in migraine. Neurology
57:334–336
4. Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, Kim JH,
Im WS, Kang L, Park JE, Park HJ, Park HK, Song EC, Lee SK,
Kim M, Roh JK (2008) Decreased number and function of
endothelial progenitor cells in patients with migraine. Neurology
70:1510–1517
5. Gudmundsson LS, Aspelund T, Scher AI, Thorgeirsson G, Joh-
annsson M, Launer LJ, Gudnason V (2009) C-reactive protein in
migraine sufferers similar to that of non-migraineurs: the Rey-
kjavik Study. Cephalalgia 29:1301–1310
6. GuldikenB,GuldikenS,DemirM,TurgutN,KabayelL,OzkanH,
Ozcelik E, Tugrul A (2008) Insulin resistance and high sensitivity
C-reactive protein in migraine. Can J Neurol Sci 35:448–451
7. Welch KM, Brandes AW, Salerno L, Brandes JL (2006)
C-reactive protein may be increased in migraine patients who
present with complex clinical features. Headache 46:197–199
8. Vanmolkot FH, de Hoon JN (2007) Increased C-reactive protein
in young adult patients with migraine. Cephalalgia 27:843–846
9. Kurth T, Ridker PM, Buring JE (2008) Migraine and biomarkers
of cardiovascular disease in women. Cephalalgia 28:49–56
10. Liew G, Wang JJ, Mitchell P (2007) Migraine and coronary heart
disease mortality: a prospective cohort study. Cephalalgia
4:368–371
11. Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G, Diener
HC, Buring JE (2007) Migraine and risk of cardiovascular disease
in men. Arch Intern Med 167:795–801
12. Agostoni E, Fumagalli L, Santoro P, Ferrarese C (2004) Migraine
and stroke. Neurol Sci 25(Suppl 3):123–125
13. Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari
MD, Launer LJ (2005) Cardiovascular risk factors and migraine:
the GEM population-based study. Neurology 64:614–620
14. Ridker PM (2001) Role of inﬂammatory biomarkers in prediction
of coronary heart disease. Lancet 358:946–948
15. Scho ¨nbeck U, Varo N, Libby P, Buring J, Ridker PM (2001)
Soluble CD40L and cardiovascular risk in women. Circulation
104:2266–2268
16. Prasad KS, Andre P, Yan Y, Phillips DR (2003) The platelet
CD40L/GP IIb-IIIa axis in atherothrombotic disease. Curr Opin
Hematol 10:356–361
17. Bosco D, Belﬁore A, Fava A, De Rose M, Plastino M, Ceccotti C,
Mungari P, Iannacchero R, Lavano A (2008) Relationship
between high prolactin levels and migraine attacks in patients
with microprolactinoma. J Headache Pain 9:103–107
18. Silberstein SD, Meriam GR (1993) Sex hormones and headache.
J Pain Symptom Manage 8:98–114
19. Fanciullacci M, Alessandri M, Del Rosso A (2000) Dopamine
involvement in the migraine attack. Funct Neurol 15(Suppl
3):171–181
20. Headache Classiﬁcation Sub-Committee of the International
Headache Society (2004) International classiﬁcation of headache
disorders, 2nd edn. Cephalalgia 24:1–160
21. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ,
Boersma E, Zeiher AM, Simoons ML (2003) CAPTURE Study
Investigators. Soluble CD40 ligand in acute coronary syndromes.
N Engl J Med 348:1104–1111
22. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo
R, Gibson CM, Cannon CP, Braunwald E, Schonbeck U (2003)
Soluble CD40L: risk prediction after acute coronary syndromes.
Circulation 108:1049–1052
23. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R,
Tomandl B, Stumpf C, Eskaﬁ S, Raaz D, Schmeisser A, Yilmaz
A, Ludwig J, Neundorfer B, Daniel WG (2003) Upregulation of
CD40-CD40 ligand (CD154) in patients with acute cerebral
ischemia. Stroke 34:1412–1418
24. Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Sisman AR,
Yuksel F, Yesil S (2010) The levels of soluble CD40 ligand and
C-reactive protein in normal weight, overweight and obese peo-
ple. Clin Med Res 8:89–95
25. Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M,
Tugrul A (2007) The levels of circulating markers of athero-
sclerosis and inﬂammation in subjects with different degrees of
body mass index: soluble CD40 ligand and high-sensitivity
C-reactive protein. Thromb Res 119(1):79–84
26. Neubauer H, Setiadi P, Gu ¨nesdogan B, Pinto A, Bo ¨rgel J, Mu ¨gge
A (2010) Inﬂuence of glycaemic control on platelet bound CD40-
CD40L system, P-selectin and soluble CD40 ligand in Type 2
diabetes. Diabet Med 27:384–390
27. Yuan M, Ohishi M, Wang L, Raguki H, Wang H, Tao L, Ren J
(2010) Association between serum levels of soluble CD40/CD40
ligand and organ damage in hypertensive patients. Clin Exp
Pharmacol Physiol 37:848–851
28. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002)
Platelet-derived CD40L: the switch-hitting player of cardiovas-
cular disease. Circulation 106:896–899
29. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P (1997)
Activation of monocyte/macrophage functions related to acute
atheroma complication by ligation of CD40: induction of colla-
genase, stromelysin, and tissue factor. Circulation 96:396–399
30. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schonbeck U, Blake
MA, Gerhard M, Ridker PM, Libby P, Lee RT (2003) Soluble
CD40 ligand levels indicate lipid accumulation in carotid ather-
oma: an in vivo study with high-resolution MRI. Arterioscler
Thromb Vasc Biol 23:e11–e14
31. Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N,
Schonbeck U (2002) Induction of tissue factor expression in
human endothelial cells by CD40 ligand is mediated via activator
protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem
277:25032–25039
32. Bath PM, Butterworth RJ (1996) Platelet size: measurement,
physiology and vascular disease. Blood Coagul Fibrinolysis
7:157–161
33. Sharp DB, Bath PMW, Martin JF, Martin JF, Beswick AD, El-
wood PC (1995) Cigarette smoking sensitizes and desensitizes
impedance-measured ADP-induced platelet aggregation in whole
blood. Thromb Haemost 74:730–735
34. Leira R, Sobrino T, Rodriguez-Yanez M, Blanco M, Arias S,
Castillo J (2007) Mmp-9 immunoreactivity in acute migraine.
Headache 47:698–702
35. Kiener PA, Moran-Davis P, Rankin BM, Wahl AF, Aruffo A,
Hollenbaugh D (1995) Stimulation of CD40 with puriﬁed soluble
gp39 induces proinﬂammatory responses in human monocytes.
J Immunol 155:4917–4925
36. Caux C, Massacrier C, Vanbervliet B, Dubois B, Van Kooten
C, Durand I, Banchereau J (1994) Activation of human den-
dritic cells through CD40 cross-linking. J Exp Med 180:1263–
1272
37. Yellin MJ, Winikoff S, Fortune SM, Baum D, Crow MK,
Lederman S, Chess L (1995) Ligation of CD40 on ﬁbroblasts
induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation
and IL-6 production and proliferation. J Leukoc Biol 58:209–216
38. Galy AH, Spits H (1992) CD40 is functionally expressed on
human thymic epithelial cells. J Immunol 149:775–782
39. Sarchielli P, Alberti A, Baldi A, Coppola F, Rossi C, Pierguidi L,
Floridi A, Calabresi P (2006) Proinﬂammatory cytokines, adhe-
sion molecules, and lymphocyte integrin expression in the
internal jugular blood of migraine patients without aura assessed
ictally. Headache 46:200–207
40. de Carvalho JF, Hanaoka B, Szyper-Kravitz M, Shoenfeld Y
(2007) C-Reactive protein and its implications in systemic lupus
erythematosus. Acta Reumatol Port 32:317–322
J Headache Pain (2011) 12:355–360 359
12341. Awaki E, Takeshima T, Takahashi K (1989) A neuroendocrino-
logical study in female migraineurs: prolactin and thyroid stim-
ulating hormone responses. Cephalalgia 9:187–193
42. Murialdo G, Martignoni E, De Maria A, Bonura ML, Sances G,
Bono G, Polleri A (1986) Changes in the dopaminergic control of
prolactin secretion and in ovarian steroids in migraine. Cepha-
lalgia 6:43–49
43. Peres MF, Sanchez del Rio M, Seabra ML, Tuﬁk S, Abucham J,
Cipolla-Neto J, Silberstein SD, Zukerman E (2001) Hypotha-
lamic involvement in chronic migraine. J Neurol Neurosurg
Psychiatry 71:747–751
44. Ali Masoud S, Fakharian E (2005) Serum prolactin and migraine.
Ann Saudi Med 25:489–491
45. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I,
Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G,
Alevizaki M, Sﬁkakis PP, Papamichael C (2009) Prolactin and
preclinical atherosclerosis in menopausal women with cardio-
vascular risk factors. Hypertension 54:98–105
46. Serri O, Li L, Mamputu JC, Beuachamp MC, Maingrette F,
Renier G (2006) The inﬂuences of hyperprolactinemia and
obesity on cardiovascular risk markers: effects of cabergoline
therapy. Clin Endocrinol 64:336–370
47. Lean ˜os-Miranda A, Ma ´rquez-Acosta J, Ca ´rdenas-Mondrago ´n
GM, Chinolla-Arellano ZL, Rivera-Lean ˜os R, Bermejo-Huerta S,
Romero-Arauz J, Alvarez-Jime ´nez G, Ramos-Leo ´n J, Ulloa-Ag-
uirre A (2008) Urinary prolactin as a reliable marker for pre-
eclampsia, its severity, and the occurrence of adverse pregnancy
outcomes. J Clin Endocrinol Metab 93:2492–2499
48. Reuwer AQ, Twickler MT, Hutten BA, Molema FW, Wareham
NJ, Dallinga-Thie GM, Bogorad RL, Gofﬁn V, Smink-Bol M,
Kastelein JJ, Boekholdt SM, Khaw KT (2009) Prolactin levels
and the risk of future coronary artery disease in apparently
healthy men and women. Circ Cardiovasc Genet 2:389–395
49. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Go ¨zu ¨ H, Sezgin O,
Haklar G, Akalin S (2003) Endothelial function, insulin sensi-
tivity and inﬂammatory markers in hyperprolactinemic pre-
menopausal women. Eur J Endocrinol 149:187–193
360 J Headache Pain (2011) 12:355–360
123